RxDoctor Payments DataLook up a doctor →

Julia Wen, MD

Cardiovascular Disease · Baltimore, MDNPI 1245208982

Payments from drug & device makers

$42,896in general payments, 2019–2025

Across 1,160 payments — averaging $36.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • AbbVie$4K
  • Novo Nordisk$4K
  • Amgen$3K
  • Viiv Healthcare Company$3K
  • Johnson & Johnson$3K
  • plus $22K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)95$4,282
AbbVie(2 entities)86$3,882
Novo Nordisk119$3,805
Amgen(2 entities)57$3,282
Viiv Healthcare Company99$3,251
Johnson & Johnson(2 entities)77$2,621
Biohaven Pharmaceuticals, Inc.8$1,833
Novartis54$1,622
GSK36$1,586
Lilly USA, LLC68$1,547
Merck58$1,424
Esperion Therapeutics, Inc.22$1,290
Gilead32$1,255
Pfizer29$1,173
Boehringer Ingelheim43$1,102
Bayer17$890
Amarin Pharma, Inc.23$613
Sanofi-aventis U.S. LLC14$585
Paratek Pharmaceuticals, Inc.12$569
E.r. Squibb & Sons, L.L.C.14$531
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC36$498
Axsome Therapeutics, Inc.18$462
Biohaven Pharmaceutical Holding Company Ltd.5$419
Phathom Pharmaceuticals, Inc.4$375
Jazz Pharmaceuticals Inc.9$368
Idorsia Pharmaceuticals US Inc10$316
Kowa Pharmaceuticals America, Inc.17$315
Daiichi Sankyo Inc.10$281
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$272
Scpharmaceuticals Inc.4$231
Boston Scientific3$174
Bausch Health US, LLC10$173
Nestle Healthcare Nutrition Inc.3$154
Takeda Pharmaceuticals U.S.A., Inc.10$154
Astellas Pharma US Inc4$145
Lexicon Pharmaceuticals, Inc.1$125
Avanir Pharmaceuticals, Inc.1$125
Radius Health, Inc.6$123
Insmed, Inc.1$116
Eisai Inc.6$109
Exact Sciences4$103
Sumitomo Pharma America, Inc.4$98
Janssen Products, LP1$88
Otsuka America Pharmaceutical, Inc.3$75
Almatica Pharma LLC2$55
Arbor Pharmaceuticals, Inc.3$52
Medicure Pharma Inc.2$42
Sanofi1$40
Irhythm Technologies, Inc.2$36
Medtronic1$33
Abbott2$26
Corcept Therapeutics1$21
Corium, LLC1$20
Kiniksa Pharmaceuticals, Ltd.1$18
Theratechnologies Inc.1$18
Preventice Services, LLC1$18
Sanofi Pasteur Inc.1$17
Vistapharm, Inc.1$16
QOL Medical, LLC1$15
Nabriva Therapeutics, PLC1$15

How this compares

$42,896 in reported general payments places this provider in the 90th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland →

Medicare billing

Part B allowed, 2024
$308,405
Medicare patients
271
Services billed
2,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Baltimore

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →